Trovagene Inc. (NASDAQ:TROV) traded up 2.5% during trading on Wednesday . The company traded as high as $5.98 and last traded at $5.73, with a volume of 783,787 shares changing hands. The stock had previously closed at $5.59.

A number of equities research analysts recently commented on the stock. Cantor Fitzgerald lowered shares of Trovagene from a “buy” rating to a “hold” rating and lowered their price target for the company from $9.00 to $5.00 in a report on Monday, April 25th. Piper Jaffray Cos. lowered shares of Trovagene from an “overweight” rating to a “neutral” rating and upped their price target for the company from $5.26 to $8.00 in a report on Monday, April 25th. Maxim Group upped their price target on shares of Trovagene from $9.00 to $12.00 and gave the company a “buy” rating in a report on Friday, August 5th. Zacks Investment Research upgraded shares of Trovagene from a “sell” rating to a “hold” rating in a report on Wednesday, July 13th. Finally, Leerink Swann lowered shares of Trovagene from an “outperform” rating to a “sector perform” rating in a report on Tuesday, April 26th. Six analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $7.13.

The company’s market cap is $169.43 million. The stock’s 50-day moving average price is $5.14 and its 200 day moving average price is $4.94.

Trovagene (NASDAQ:TROV) last released its earnings results on Thursday, August 4th. The company reported ($0.34) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by $0.03. On average, analysts predict that Trovagene Inc. will post ($1.33) earnings per share for the current year.

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.